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ttp://dx.doi.org/10.1016/j.ajpath.2014.09.016Recent studies underline the potential relevance of microglial innate immune activation in Alzheimer
disease. Primary mouse microglia that lack prostaglandin E2 receptor subtype 2 (EP2) show decreased
innate immune-mediated neurotoxicity and increased amyloid b (Ab) peptide phagocytosis, features that
were replicated in vivo. Here, we tested the hypothesis that scavenger receptor CD36 is an effector of EP2-
regulated Ab phagocytosis. CD36 expression was 143-fold greater in mouse primary microglia than in
primary astrocytes. Three different means of suppressing EP2 signaling increased and an agonist of EP2
decreased CD36 expression in primary wild-type microglia. Activation of Toll-like receptor (TLR) 3, TLR4,
and TLR7, but not TLR2 or TLR9, reduced primary microglial CD36 transcription and cell surface CD36
protein and reduced Ab42 phagocytosis as well. At each step, the effects of innate immune activation on
CD36 were reversed by at least 50% by an EP2 antagonist, and this partial rescue of microglia Ab42
phagocytosis was largely mediated by CD36 activity. Finally, we showed in hippocampus of wild-type mice
that innate immune activation suppressed CD36 expression by an EP2-dependent mechanism. Taken
together with results of others that found brain clearance of Ab peptides and behavioral improvements
mediated by CD36 in mice, regulation of CD36-mediated Ab phagocytosis by suppression of EP2 signaling
may provide a new approach to suppressing some aspects of Alzheimer disease pathogenesis.
(Am J Pathol 2015, 185: 230e239; http://dx.doi.org/10.1016/j.ajpath.2014.09.016)Supported by NIH grants ES016754, ES007032, AG005136, and
NS062684; and the Nancy and Buster Alvord Endowment.
Disclosures: None declared.Observational studies in patients and experimental studies
that use a variety of model systems have concluded that
affected regions of the brain in Alzheimer disease (AD)
experience a proinﬂammatory, pro-oxidative state.1 Indeed,
recent studies have highlighted several genes involved in the
innate immune response whose variants are associated with
increased risk of AD, especially the TREM2 gene.2e4 TREM2
encodes the triggering receptor expressed on myeloid cells-2,
a protein expressed by myeloid lineage cells, including
microglia in brain, which can function as a receptor for
phagocytosis,5 modulate the innate immune response in
brain,6,7 and diminish immune response through several
signaling pathways, including suppression of Toll-like re-
ceptor (TLR) signaling.8,9
The prostaglandin (PG) pathway, a cascade initiated by
enzyme-catalyzed synthesis of PGH2 from arachidonic acid by
the cyclooxygenases (COXs), COX-1 orCOX-2, is an essential
component of the innate immune response. Multiple studiesstigative Pathology.
.have reproducibly shown that nonselective COX or COX-
2eselective inhibition by nonsteroidal anti-inﬂammatory
drugs (NSAIDs) can suppress amyloid b (Ab) accumulation
and associated behavioral changes in transgenic mouse models
of AD10 and can reduce the risk of AD dementia in people by
approximately 60%.11 Together these results suggest that
NSAIDs may effectively suppress some aspect of what is now
appreciated to be early steps in AD pathogenesis.12 These
compelling experimental model and human data formed the
rationale for multiple clinical trials. Two clinical trials targeted
what is now understood to be relatively advancedAD: one with
NSAIDs in AD dementia and one with NSAIDs in mild
cognitive impairment, a diagnostic group enriched for pro-
dromal AD; both failed.13,14 A third trial targeted early-stage
EP2-Suppressed Phagocytosis via CD36AD,15 similar to the epidemiologic cohorts, but was terminated
because of toxicity, likely related to perturbation of prostacyclin
and thromboxane metabolism.16e18 Despite these disap-
pointing therapeutic outcomes, some data suggest pharmaco-
dynamic effects of NSAIDs in the central nervous system of
patients with AD.19,20
We and others have sought to disentangle the potentially
beneﬁcial effects of NSAIDs in early AD pathogenesis from
toxic effects by focusing on speciﬁc PG receptors distal in the
signaling cascade rather than proximal COX inhibition.21e23
PGE2 is the principal proinﬂammatory PG, and increased
PGE2 concentrations in cerebrospinal ﬂuid have been found in
patients with AD,24 particularly early in the disease process.25
In addition, the inducible form of PGE2 synthase is increased in
AD brain and is a key component in Ab-mediated neurotox-
icity in amousemodel of AD.26We, therefore, have focused on
PGE2 and its functionally antagonistic receptor subtypes, EP1
to EP4, which are widely expressed in central nervous system
cells, including microglia, astrocytes, and neurons.21 Primary
microglia from mice homozygous deﬁcient for the EP2
gene (PTGER2; EP2/) have the highly desirable dual
phenotype of suppressed TLR-activated microglia-mediated
neurotoxicity that depends on the adaptor protein DOCK2 and
enhanced microglial phagocytosis of Ab that is DOCK2
independent.27e29 These studies show that microglial EP2 is
necessary for lipopolysaccharide-induced microglia-mediated
neurotoxicity in microgliaeneuron cocultures through regula-
tion of inducible nitric oxide synthase and COX-2 and subse-
quent neurotoxic cytokine production, including IL-1b
production,27 and indicate EP2-dependent neurotoxicity in
EP2/ microglia, with reduced paracrine neurotoxicity in
response to aggregated Ab in neuronemicroglia cocultures.28
Recently, these ﬁndings were conﬁrmed in mice with condi-
tional deletion of EP2 in myeloid lineage cells and in bone
marrow transplant experiments.30,31
Microglial phagocytosis is mediated largely by a class of
surface proteins called scavenger receptors. CD36, a type B
scavenger receptor originally identiﬁed as a receptor for long-
chain fatty acids and oxidized low-density lipoprotein, is a
microglial binding site for Ab,32 facilitates intracellular nucle-
ation of Ab peptides into ﬁbrils,33 and mediates some of the
biological effects of Ab peptides, including innate immune
activation and oxidative stress.34e36 CD36 is expressed on
microglia in AD brains.34 CD36 overexpression in human brain
correlates with b-amyloid deposition but not with AD; it is
undetectable in healthy brains without Ab deposition.37 We are
unaware of any data to link the speciﬁc PG receptors with CD36
function. Here, we tested the hypothesis that EP2 suppression of
Ab phagocytosis is mediated, at least in part, by CD36.
Materials and Methods
Materials
Dulbecco’s modiﬁed Eagle’s medium/F-12 medium and
fetal bovine serum were purchased from HycloneThe American Journal of Pathology - ajp.amjpathol.orgLaboratories (Logan, UT). Papain and DNase I were from
Worthington Biochemical (Lakewood, NJ). Butaprost,
NS-398, 17-phenyl trinor PGE2, CAY10598, ZK118182,
17-phenyl trinor PGF2a, carbaprostacyclin, U-46619, AH
6809, and CD36 blocking antibody (Clone JC63.1) were
from Cayman Chemical Company (Ann Arbor, MI).
Dibutyryl cAMP, forskolin, tribromoethanol (Avertin),
and polyinosinic-polycytidylic acid (PIC; TLR3 ligand)
were from Sigma-Aldrich (St. Louis, MO). Pam3CSK4
(TLR2 ligand), loxoribine (TLR7 ligand), and CpG (TLR9
ligand) were from Invivogen (San Diego, CA). Lipo-
polysaccharide (TLR4 ligand) was purchased from Cal-
biochem (La Jolla, CA). pHrodo ﬂuorogenic dye was from
Invitrogen (Carlsbad, CA). b Amyloid 1-42 (Ab42) was
from American Peptide Company (Sunnyvale, CA).
Animals
C57BL/6 mice and CD36/ (B6.129S1-Cd36tm1Mfe/J)
mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). EP2/ mice were a gift from Dr. Richard
Breyer (Vanderbilt University, Nashville, TN). The
animals were maintained in a speciﬁc pathogen-free
environment. All procedures were approved by the
University of Washington Institutional Animal Care and
Use Committee.
Stereotactic Intracerebroventricular Injection
Ten-week-old male mice were anesthetized with isoﬂurane
inhalation and placed in a stereotactic instrument. After the
skull was exposed through skin incision, a cranial window
(2 to 3 mm) on the left lateral ventricle was opened by
drilling with a small burr bit. Five microliter of reagent
was injected over a period of 5 minutes by using a
Hamilton microsyringe; injections were 200 ng of AH
6809, 50 ng of PIC, AH 6809 plus PIC, or vehicle. After
injection, the mice were placed on an isothermal pad and
continuously observed until recovery. Twenty-four hours
after injection, the mice were sacriﬁced by i.p. injection of
tribromoethanol and perfused with ice-cold phosphate-
buffered saline, and brain tissues were rapidly harvested
for analysis.
Cell Culture and Exposure
Primary microglia and astrocytes were isolated from brains
of newborn mice and cultured as previously described.38,39
Medium concentrations of PGE2 were measured by ELISA
exactly as described previously.38 Cells were incubated with
the compounds described at the indicated concentrations
and times. We note that, although EP antagonist AH 6809
has nearly equal afﬁnity for EP1 and DP1 in human tissue,40
it has been shown to be selective for EP2 in mouse tissue.41
EP agonist butaprost was used at 20 mmol/L, based on
previous studies that showed effects up to 100 mmol/L.42,43231
Li et alQuantitative Real-Time PCR
Total RNAwas extracted from primarymicroglia, astrocytes, or
brain tissues by using RNeasy Mini Kit (Qiagen, Valencia,
CA). Reverse transcription was performed with Omniscript RT
Kit (Qiagen). TaqMan probes and primers (Mm01135198_m1
for CD36, fMm99999915_g1 for GAPDH) were purchased
from Applied Biosystems (Carlsbad, CA). PCR were per-
formed on an Applied Biosystems ViiA 7 Real-Time PCR
System by using the relative quantitative method.
Flow Cytometric Analysis of Cell Surface CD36 in
Primary Microglia
Microglia were preincubated with 10 mg/mL of anti-mouse
CD16/CD32 antibody (BD Biosciences, San Jose, CA) for 5
minutes on ice to block Fc receptoremediated binding. The
cells were then incubated with 5 mg/mL of phycoerythrin-
conjugated CD36 or mouse IgA control (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) for 30 minutes on ice
in the dark. Thereafter, microglia were washed twice with
phosphate-buffered saline and resuspended in 4% para-
formaldehyde for ﬁxation. The ﬂuorescence intensity was
determined by BD FACScan ﬂow cytometry.
Ab42 Phagocytosis in Primary Microglia
Microglia were incubated with 5 mmol/L pHrodo-labeled
Ab42 for 2 hours at 37C. The nonspeciﬁc signal was
determined by incubation of microglia with the same con-
centration of labeled Ab42 for 2 hours at 4C. Thereafter,
microglia were washed three times in phosphate-buffered
saline and ﬁxed in 4% paraformaldehyde. The samples
were analyzed by LSRII ﬂow cytometry (BD Biosciences)
with a 561-nm excitation laser.
CD36 Expression in CHO Cells
Human CD36was expressed in Chinese hamster ovary (CHO)
cells as described by others.44 Brieﬂy, cells were maintained in
Ham’s F-12 medium that contained 10% fetal bovine serum
and penicillin/streptomycin. Human full-length CD36 cDNA
was obtained from GE Healthcare (Lafayette, CO) and cloned
into the expression vector pIRES2-EGFP at EcoRI and XbaI
sites. The recombinant vector or empty vector was transfected
into CHO cells by Lipofectamine 2000 according to the
manufacturer’s protocol. The expression of CD36 was
conﬁrmed by quantitative PCR with Taqman expression
assay. Two days after transfection, cells were collected for
phagocytosis assay and inhibition with sulfosuccinimidyl
oleate (SSO) as described by others.45
Statistical Analysis
Statistical analyses were performed with GraphPad Prism 5
(GraphPad Inc., SanDiego, CA) with a set to 0.05. AllP values232presented in the text or ﬁgures were corrected for multiple
comparisons when appropriate with the method of Bonferroni.
Results
Microglia Express Much More CD36 than Astrocytes
Microglia, and less so astrocytes, are cellular effectors of
innate immune response in the cerebral cortex. CD36
expression in primary wild-type (WT) cultures of microglia
and astrocytes prepared from the same ﬁve mice was
determined by quantitative real-time PCR with each sample
normalized to endogenous control GAPDH. CD36 expres-
sion in microglia was on average 143-fold greater in
microglial than in astrocytes (P < 0.0001). For this reason,
subsequent experiments focused on microglia.
Down-Regulation of CD36 Expression by Speciﬁc TLR
Activation
Because many endogenous activators of innate immune
response, including Ab,46e49 act through TLRs and because
one function of TREM2 is to regulate TLR signaling,8 we
measured primary WT mouse microglia CD36 expression
after exposure for 18 hours to speciﬁc TLR activators that
are known to activate microglia.38 Activators of TLR3,
TLR4, and TLR7, but not TLR2 or TLR9, suppressed
microglia expression of CD36 (Figure 1A). A seven-point
time series (Figure 1B) showed no change in CD36
expression after 2 hours of PIC exposure (1.03  0.05
CD36 mRNA compared with time 0), but after 4 hours of
exposure CD36 mRNA was reduced to 0.74  0.03 and
continued to decrease linearly to 0.16  0.03 at 18 hours
(R2Z 0.95, P < 0.0001). A similar time course for medium
PGE2 was approximately complementary with 23  2
pg/mL at time 0 and increased to 2199  64 pg/mL at 18
hours (P < 0.0001). Other scavenger receptors also were
altered by PIC incubation for 18 hours: microglial expres-
sion of SR-A1 was increased 3.1-  0.7-fold (P < 0.01) and
SR-B1 was decreased 0.25-  0.06-fold (P < 0.001)
compared with vehicle-exposed cultures.
Regulation of CD36 Expression by EP2
We next surveyed speciﬁc agonists to prostanoid receptors EP,
DP, FP, IP, and TP to determine which, if any, speciﬁc product
of COX might contribute to innate immune-mediated reduc-
tion in CD36 expression. Agonists of EP2 or EP4 mimicked
the effect of innate immune activation by signiﬁcantly
reducing CD36 expression in primary WT mouse microglia,
whereas agonists of EP1 or TP had a functionally antagonistic
effect; agonists of FP, IP, and DP had no signiﬁcant effect on
CD36 at known effective concentrations (Figure 2A).39 In
contrast, a COX-2eselective inhibitor, an EP2 antagonist, and
EP2/ microglia had progressively increasing microglial
CD36 expression. Activation of the innate immune responseajp.amjpathol.org - The American Journal of Pathology
Figure 2 Effects of eicosanoid receptors with and without innate immune
activation on CD36 mRNA expression by mouse primary microglia. RNA was
isolated from cultures prepared from wild-type mice (dark bars) or EP2/ mice
(light bar) after 18 hours of incubation. Results from quantitative real-time PCR
were normalized to endogenous control GAPDH. A:Microglia exposed to vehicle
or 5 mmol/L agonists of EP1 (17-phenyl trinor PGE2), 20 mmol/L EP2 (butap-
rost), 2.5 mmol/L EP4 (CAY10598), 10 mmol/L DP (ZK118182), 10 mmol/L FP
(17-phenyl trinor PGF2a), 10 mmol/L IP (carbaprostacyclin), or 5 mmol/L TP
(U-46619). B: Microglia exposed to vehicle or 20 mmol/L COX-2eselective
inhibitor (NS398), 20 mmol/L EP2 antagonist AH, and TLR activators (PIC for
TLR3at 20mg/mL, LPS for TLR4at 1mg/mL, or loxoribine for TLR7at 0.5mmol/L)
with orwithout 20mmol/LAH. C:Microglia exposed to20mmol/L butaprost, 250
mmol/L db cAMP, or 10 mmol/L forskolin. Data are expressed as means  SEM.
nZ3 to12per group. *P< 0.05, **P< 0.01, and***P< 0.001 for Bonferroni-
corrected repeated pair comparisons with vehicle; yP< 0.05 and yyP< 0.001 for
Bonferroni-correctedpaired comparisons between twoexperimental groups. AH,
AH 6809; COX-2, cyclooxygenase 2; db cAMP, dibutyryl cAMP; EP2/, homo-
zygous EP2 deﬁcient; LPS, lipopolysaccharide; PGE2, prostaglandin E2; PIC,
polyinosinic-polycytidylic acid; TLR, Toll-like receptor; Veh, vehicle.
Figure 1 Effects of TLR activators on CD36 mRNA expression. A: WT
mouse primary microglia were treated with Veh or 1 mg/mL activator of
TLR2 (Pam3CSK4), 20 mg/mL TLR3 (PIC), 1 mg/mL TLR4 (lipopolysaccha-
ride), 1 mmol/L TLR7 (loxoribine), or 1 mmol/L TLR9 (CpG) for 18 hours.
RNA was extracted for quantitative real-time PCR. CD36 mRNA values in
each sample were normalized to endogenous control GAPDH. B: WT mouse
primary microglia were treated with 20 mg/mL PIC for the indicated times.
CD36 mRNA was assessed by quantitative real-time PCR, and results were
normalized to GAPDH. Medium PGE2 was assayed by ELISA. Data are
expressed as means  SEM. nZ 3 per group. ***P < 0.001 for Bonferroni-
corrected repeated pair comparisons with vehicle (A) or with value at time 0 (B).
PGE2, prostaglandin E2; PIC, polyinosinic-polycytidylic acid; TLR, Toll-like
receptor; Veh, vehicle; WT, wild-type.
EP2-Suppressed Phagocytosis via CD36with agents speciﬁc for TLR3, TLR4, or TLR7 each repro-
ducibly decreased microglial CD36 expression, an effect that
was mostly reversed for each TLR activator with an EP2
antagonist (AH 6809) (Figure 2B); although reversal by AH
6809 was greatest in the context of TLR3 activation. A se-
lective antagonist of EP4 is not commercially available.50,51
EP2 and EP4 are stimulatory G-protein-couple receptors, but
because EP2 also can activate G-proteineindependent second
messenger signaling,52 we tested the effect of directly
manipulating cAMP signaling on CD36 expression; dibutyryl
cAMP or forskolin decreased CD36 mRNA values by the
same magnitude as butaprost alone (Figure 2C). These data
show that multiple eicosanoid products of COX exert tonic
control over CD36 expression inmouse primary microglia and
that among these EP2 or EP4 activation suppresses CD36
expression to an amountmatched by direct activation of cAMP
second messenger signaling. Finally, results by using an
antagonist show that EP2 signaling is responsible for most
reduced microglial CD36 expression with TLR-activated
innate immune response.The American Journal of Pathology - ajp.amjpathol.org 233
Li et alCD36 expression is transcriptionally regulated, but we
nevertheless sought to validate the changes observed in
microglia CD36 mRNA expression with changes in CD36
protein. Flow cytometric analysis of primary WT mouse
microglia labeled with phycoerythrin-conjugated anti-CD36
antibody; 24 hours of exposure to butaprost, an EP2 agonist,
signiﬁcantly reduced CD36 cell surface protein to values
that were proportionate to mRNA reduction (Figure 3).
Conversely, exposure to AH 6809 increased CD36 cell
surface protein values. These results are consistent with the
known transcriptional regulation of CD36 protein and
indicate that changes in microglia cell surface CD36 protein
follow the same pattern as CD36 mRNA in response to an
agonist or antagonist of EP2.Inhibition of CD36-Dependent Phagocytosis by EP2
Activation
Our next series of experiments used primaryWT and CD36/
mouse microglia to investigate whether CD36 mediated EP2Figure 3 Effects of TLR3 activator and prostaglandin EP2 signaling on
CD36 protein. WT microglia were treated with 20 mmol/L butaprost, 20
mmol/L AH, 20 mg/mL PIC, or a combination of PIC and AH for 24 hours.
CD36 protein on cell surface was assessed by staining with PE-labeled anti-
CD36 antibody or isotype-matched PE-IgA (isotype control). A: Represen-
tative histogram from ﬂow cytometric assay of CD36 immunoﬂuorescence.
B: Geometric means of ﬂuorescence intensity was normalized to vehicle.
Data are expressed as geometric means of ﬂuorescence intensity  SEMs.
n  3 per group. **P < 0.01 and ***P < 0.001 for Bonferroni-corrected
repeated paired comparisons with vehicle; yP < 0.05 and yyP < 0.001 for
Bonferroni-corrected paired comparisons between two experimental
groups. AH, AH 6809; Buta, butaprost; CT, control; EP2, E2 receptor sub-
type 2; PE, phycoerythrin; PIC, polyinosinic-polycytidylic acid; TLR, Toll-
like receptor; WT, wild-type.
234effects on Ab42 phagocytosis. We quantiﬁed phagocytosis of
Ab42 labeled with a pH-sensitive dye (pHrodo) and under the
same conditions that affected CD36 mRNA and cell surface
protein values (shown in Figures 2 and 3). Butaprost
signiﬁcantly decreased Ab42 phagocytosis in WT microglia,
validating previous experiments from our laboratory that
used EP2/ microglia with synthetic Ab42 and human
brain-derived Ab peptides (Figure 4A).28,30,53 TLR3 acti-
vation from PIC exposure signiﬁcantly reduced Ab42
phagocytosis byWTmicroglia, and this immune suppression
was signiﬁcantly but partially reversed by AH 6809, paral-
leling the effect of PIC on CD36 expression and indicating
that EP2 activation accounted for approximately one-half of
PIC-suppressed Ab42 phagocytosis. CD36 inhibitor SSO
reversed this rescue, consistent with CD36-dependent
phagocytosis. Because SSO may have actions in addition
to inhibiting CD36, we sought to validate this ﬁnding with
three different experiments. In the ﬁrst, we used AH 6809
(coincubated with control IgA) to achieve increased Ab42
phagocytosis (P < 0.01) that paralleled increased CD36
expression (Figure 4B); this prophagocytic effect of AH
6809 was completely blocked by a CD36 neutralizing anti-
body. Consistent with this, CD36 blocking antibodies did not
further inhibit butaprost-treated cells. In the second set of
experiments, we compared phagocytosis in microglia pre-
pared from WT and CD36/ mice (Figure 4C). CD36/
microglia had reduced Ab42 phagocytosis compared with
WT microglia (P < 0.001). Importantly, increased Ab42
phagocytosis seen with exposure to AH 6809 was ablated in
CD36/ microglia, whereas butaprost had no signiﬁcant
effect on Ab42 phagocytosis in these cells. In combination,
results from WT microglia with the use of SSO or a CD36-
neutralizing antibody and from CD36/ microglia support
the conclusion that the effects of EP2 activation on Ab42
phagocytosis are largely mediated by CD36. Finally, we
transfected CHO cells with human CD36 as described by
others.44 Vector-transfected CHO cell uptake of Ab42 was
deﬁned as 100%. Expression of human CD36 signiﬁcantly
increased uptake of Ab42 by CHO cells to 182%  6% of
vehicle-transfected control (P < 0.001), similar to what has
been reported previously by others.44 Also validating the
results of others,45 exposure to SSO by using the same
method as described above for mouse primary microglia
completely inhibited Ab42 uptake by human CD36-
expressing CHO cells to 102%  9% of vehicle-transfected
control; Ab42 uptake by vehicle-transfected CHO cells was
not signiﬁcantly altered by SSO (94%  8% of vector-
transfected cells without SSO).
Reduced CD36 Expression by PIC Largely Depends on
EP2 in Mouse Brain
Finally, we investigated whether EP2 regulated CD36
expression in a relevant region of WT mouse brain. Hip-
pocampal CD36 mRNA values were quantiﬁed 24 hours
after 50 ng intracerebroventricular injection of PIC into theajp.amjpathol.org - The American Journal of Pathology
EP2-Suppressed Phagocytosis via CD36left lateral ventricle with or without two different doses of
the EP2 antagonist AH 6809 (200 or 50 ng) (Figure 5). Our
results showed that direct exposure to TLR3 activator PIC
signiﬁcantly reduced ipsilateral hippocampal CD36
expression to one-half of vehicle (0.51  0.09; P < 0.05 by
Bonferroni-corrected posttest) and that this was reversed by
simultaneous exposure to AH 6809. Indeed, two-way
analysis of variance had P < 0.01 for an interaction term
between PIC and AH 6809, and Bonferroni-correctedThe American Journal of Pathology - ajp.amjpathol.orgposttests were not signiﬁcant for comparison of PIC with
PIC plus 200 ng of AH 6809. Similar results were achieved
when using 50 ng (0.86  0.21) rather than 200 ng of AH
6809 (0.81  0.22).Discussion
Considerable data from observational studies of human brain
and experimental models support the hypothesis that micro-
glial innate immune activation is a feature and possible
contributor to AD pathogenesis, a hypothesis recently rein-
forced by genetic association of AD dementia with several
genes that regulate innate immunity, especially TREM2. Re-
sults from these studies are further buttressed by compelling
epidemiologic and experimental model data that support in-
hibition of the PG cascade as an effective therapeutic approach
early in the pathogenesis of AD before clinical expression or
behavioral impairments in transgenic mouse models. Enthu-
siasm over these observational and experimental data are
tempered by failed trials that used NSAIDs to suppress innate
immunity in subjects with mild cognitive impairment or AD
dementia and the termination of an AD prevention trial
because of toxicity. Although the clinical trial results clearly
are disappointing, they do not necessarily indict the innate
immunity hypothesis for AD but rather may reﬂect limitations
of intervening too late in the course of AD and/or therapeutic
shortcomings of proximal inhibition of the PG cascade in
people. Together, these results cautiously animate pursuit of
components distal in the PG cascade as a potentially more
effective means of suppressing microglial innate immunity
while averting unwanted side effects.
Previously, with the use of primary mouse microglia, we
have shown that suppression of EP2 signaling leads to a
therapeutically desirable dual phenotype of reduced innateFigure 4 Regulation of mouse primary microglia phagocytosis of Ab42
by prostaglandin EP2 receptor signaling. After exposure to agents,
phagocytosis was determined by incubation with pHrodo-labeled Ab42 for 2
hours at 37C. Fluorescence intensities were determined by ﬂow cytometry,
and geometric means of ﬂuorescence intensity were normalized to vehicle-
exposed WT cells. A: WT microglia were pretreated with 20 mmol/L EP2
agonist butaprost, 20 mg/mL TLR3 activator PIC, or 20 mg/mL PIC plus 20
mmol/L EP2 antagonist AH 6809 for 24 hours and then incubated with
pHrodo-labeled Ab42. Cultures treated with PIC þ AH 6809 were also
incubated with 500 mmol/L CD36 inhibitor, SSO, for an additional hour
before phagocytosis assay. B: WT microglia were treated with 20 mmol/L AH
6809 or 20 mmol/L agonist butaprost for 24 hours, followed by incubation
with 10 mg/mL anti-CD36 IgA or mouse control IgA for 1 hour, and then
phagocytosis was determined. C: Primary microglia from WT or CD36/
mice were treated with 20 mmol/L EP2 antagonist AH 6809 or 20 mmol/L
agonist butaprost for 24 hours, and then phagocytosis was determined.
Data are expressed as means  SEM. nZ 3 per group (A and C); nZ 3 or 4
per group (B). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001
for Bonferroni-corrected repeated paired comparisons with vehicle;
yP < 0.05 and yyP < 0.01 for Bonferroni-corrected paired comparisons
between two experimental groups. Ab42, b-amyloid 1-42; EP2, E2 receptor
subtype 2; PIC, polyinosinic-polycytidylic acid; SSO, sulfosuccinimidyl
oleate; TLR, Toll-like receptor; WT, wild-type.
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Figure 5 Modulation of CD36 expression in mouse hippocampus by PIC
and prostaglandin E2 receptor subtype 2 antagonist AH 6809. Wild-type
mice received intracerebroventricular injection into the left lateral
ventricle with vehicle, 50 ng PIC, 200 ng AH 6809, or 50 ng PIC plus 200 ng
AH 6809. Ipsilateral hippocampus was isolated after 24 hours, mRNA values
of CD36 were determined by quantitative real-time PCR, and results were
normalized to endogenous control GAPDH. Data are expressed as
means  SEM. n Z 6 mice per group. Two-way analysis of variance (df
1,1,1, 20) had **P < 0.01 for PIC and interaction between PIC and AH
6809 but was insigniﬁcant for AH 6809 alone. Bonferroni-corrected post-
tests were signiﬁcant only for the pair with no AH 6809 (**P < 0.01) but
were insigniﬁcant for the pair with AH 6809. PIC, polyinosinic-polycytidylic
acid; Veh, vehicle.
Li et alimmune-mediated neurotoxicity and enhanced Ab phago-
cytosis, including neuritic plaque material.28 Subsequently,
we and others have validated these ﬁndings in macrophages
and in vivo in mouse brain by using homozygous deﬁcient
mice, conditional deletion mice, and bone marrow transplant
mice. Although we have made some progress in under-
standing the molecular mechanisms of EP2 regulation of
microglia-mediated neurotoxicity, the mechanisms by
which EP2 signaling regulates Ab42 phagocytosis remained
unclear. Here, we showed that scavenger receptor CD36, a
key regulator of microglia Ab42 phagocytosis, is closely
regulated by EP2 signaling in primary WT mouse microglia
both without further activation or in the context of TLR
activators. We focused our work on primary microglia
because they express the majority of CD36 among
phagocytosis-competent cells in the central nervous system.
Primary WT microglial expression of CD36 was increased
by an EP2 antagonist and decreased by an EP2 agonist; the
latter was associated with proportionately reduced CD36
cell surface protein and Ab42 phagocytosis. We showed that
speciﬁc TLR activators led to decreased microglia CD36
transcription and that this translated into reduced cell sur-
face CD36 protein and reduced Ab42 phagocytosis. At each
step in this process, we showed that the effects of innate
immune activation on CD36 could be reversed by at least
half by suppressing EP2 signaling and that the effects of
EP2 activation on Ab42 phagocytosis are largely mediated
by CD36. Together, our results from primary microglia
cultures indicated tonic control of CD36 expression by EP2
signaling, and that most innate immune-mediated suppres-
sion of Ab42 phagocytosis depended on EP2, and that this
EP2 effect was CD36 dependent.236Current data support reduced clearance as the dominant
mechanism for Ab accumulation in the most common forms
of AD (reviewed in Wildsmith et al54). Although Ab may be
transported out of brain, it also may be cleared by microglial
phagocytosis. Indeed, several lines of evidence point to Ab
phagocytosis as a potentially important process in AD.
These include the increased genetic risk of AD with TREM2
variants, reduced expression of the phagocytosis-related
protein beclin 1 in diseased brain regions and isolated
microglia from patients with AD,55,56 and reduced CD36
expression on leukocytes in patients with AD dementia or
mild cognitive impairment.57 It is important to note that,
although we have focused on its phagocytic function, the
CD36/Ab complex is pleiotropic and interacts with several
intracellular molecules, such as p130Cas, Pyk2, and Pax-
illin, and initiates signaling pathways that ultimately lead to
F-actin polymerization and cytoskeleton reorganization.58
Our results from mouse microglia conﬁrmed those from
other cell types that have shown decreased expression of
CD36 after TLR3 or TLR4 activation.59,60 We expanded
this survey to include TLR7, activation of which by an
miRNA can propagate neurodegeneration.61 Our data also
showed that the innate immune-mediated decrease in CD36
was mostly, but not fully, reversed by an EP2 antagonist,
suggesting that some other proinﬂammatory factor(s) also
inhibit microglial CD36 expression. One possibility is tumor
necrosis factor-a,62,63 although this is complicated because
tumor necrosis factor-a secretion depends in part on EP2.38
Our data also suggest EP4 as another possibility. However,
we were limited in pursuing this further because of lack of a
selective EP4 antagonist. In contrast to innate immune
activation effects on CD36 expression, a variety of anti-
inﬂammatory mediators increase CD36 expression,
including IL-4, IL-13, and peroxisome proliferator-activated
receptor g agonist.64e67 Blocking CD36 with an antibody
reduces cytokine and nitric oxide when microglia are
incubated with PrP protein.68 Although difﬁcult to classify
broadly as either proinﬂammatory or anti-inﬂammatory, we
found that an agonist of EP1 or TP also increased CD36
expression in microglia. Functional antagonism is observed
commonly among eicosanoid receptors.21 Our results point
to a dominant effect of EP2-mediated suppression of CD36
expression in the context of microglial innate immune
activation, perhaps related to its higher binding afﬁnity for
PGE2 than for EP1.
21
Our in vivo experiments showed that CD36 expression in
WT mouse hippocampus followed the same mechanisms as
microglia. Speciﬁcally, activation of innate immune
response with PIC signiﬁcantly decreased CD36 expression,
although the magnitude was somewhat less than that
observed in primary microglia. The reasons for this differ-
ence in magnitude of effect by PIC in vivo versus in vitro are
not clear from our experiments but may be related to the
inﬂuence of other cell types and clearance of the inﬂam-
magen. Regardless, our results with a highly selective
activator of TLR3 are consistent with those from ADajp.amjpathol.org - The American Journal of Pathology
EP2-Suppressed Phagocytosis via CD36transgenic mice that also observed reduced CD36 expres-
sion in the brain,63 a ﬁnding confounded by the multiple
actions of Ab peptides. Most importantly, coadministration
of AH 6809 largely reversed the effect of PIC, so much so
that there was no signiﬁcant difference between hippo-
campal CD36 mRNA values in the PIC alone group versus
the PIC plus AH 6809 group.
We did not attempt to duplicate behavioral experiments in
mice because several other laboratories already have
investigated CD36 in the context of mouse behavior and
models of immune activation or AD. Indeed, CD36-
deﬁcient mice show signiﬁcant learning impairment as
assessed by radial arm maze.69 In contrast, increased CD36
expression by peroxisome proliferator-activated receptor g/
retinoid X receptor a agonists increased microglial Ab
phagocytosis and improved cognitive performance in an AD
transgenic mouse.67 Similarly, increased CD36 expression
after brain microinjection of IL-4/IL-13 into another AD
transgenic mouse was associated with increased Ab clear-
ance and improved cognitive performance.66
Conclusions
In summary, our data are consistent with an innate immune
hypothesis for AD in which age, inherited deﬁcits, or
environmental factors impair the clearance of Ab peptides
either by reduced transport and/or by reduced phagocytosis.
This promotes accumulation of Ab peptides and other debris
that function as endogenous ligands of TLRs and other
pattern recognition receptors that activate an innate immune
response; this in turn further lowers phagocytic activity. Our
results are consistent with others in supporting a key role for
CD36 in Ab phagocytosis by microglia and highlight EP2
antagonists as an effective means to suppress this toxic
reinforcing cycle. Combined with results of others, our data
suggest that EP2 antagonists have the potential as a thera-
peutic approach to suppressing key aspects of AD
pathogenesis.
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